Biotech patent system under heat
Landmark study claims a broken intellectual property system is stopping lifesaving technologies from reaching the people who need them the most in developing and industrialized countries.
By Michael D. Christel

Editor's Page
By Christiane Truelove

R&D Business
Successfully outbidding Bristol-Myers Squibb, Eli Lilly boosts oncology capacity with $6.5 billion acquisition of biotech ImClone Systems Inc.
By Joseph Gialanella

eR&D
FDA examiners enroll in crash course on electronic submissions conducted by CDISC and its member partners.
By Joseph Gialanella

Drugs in Development
As part of a major pipeline reshuffling, Pfizer eliminates research in heart disease, obesity, and bone density, among other areas.
By Joseph Gialanella

Filed for Approval
FDA issues "complete response letters" on rheumatoid arthritis, cystic fibrosis, and breakthrough pain drugs.
By Joseph Gialanella

Amgen highlights denosumab, growth strategies
Amgen executives attempted to reassure shareholders that the biotech is back on solid ground, insisting that the next five years will make the hard times of the last two seem like a distant memory.

Backing the terminally ill
Patients rights groups continue to lobby on behalf of terminally ill patients for legal rights to expanded access programs.

Account manager ROI
Med Ad News spoke with Chris Blenk, senior principle, IMS Consulting, about how companies can measure the return on investment they receive from their account management teams.